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Abstract
Background: The granulocyte colony-stimulating factor receptor (G-CSFR) plays a critical role in maintaining
homeostatic levels of circulating neutrophils (PMN). The mechanisms modulating G-CSFR surface expression to
prevent chronic neutrophilia are poorly understood. Here, we report that neutrophil elastase (NE) proteolytically
cleaves the G-CSFR on human PMN and blocks G-CSFR-mediated granulopoiesis in vitro.
Methods: Human peripheral blood PMN isolated from healthy donors were incubated with NE. Expression of the
G-CSFR was analyzed by flow cytometry and western blot analyses. Detection of G-CSFR cleavage products from
the culture supernatants was also performed. Human bone marrow mononuclear cells were also cultured in the
presence or absence of NE to determine its effects on the proliferation of granulocyte-macrophage colony forming
units (CFU-GM).
Results: Treatment of PMN with NE induced a time-dependent decrease in G-CSFR expression that correlated with
its degradation and the appearance of proteolytic cleavage fragments in conditioned media. Immunoblot analysis
confirmed the G-CSFR was cleaved at its amino-terminus. Treatment of progenitor cells with NE prior to culture
inhibited the growth of granulocyte-macrophage colony forming units.
Conclusions: These findings indicate that in addition to transcriptional controls and ligand-induced internalization,
direct proteolytic cleavage of the G-CSFR by NE also downregulates G-CSFR expression and inhibits G-CSFR-
mediated granulopoiesis in vitro. Our results suggest that NE negatively regulates granulopoiesis through a novel
negative feedback loop.
Background
Granulocyte colony-stimulating factor (G-CSF) is the
major regulator of granulopoiesis and supports the sur-
vival, proliferation, and maturation of myeloid progeni-
tor cells along the neutrophil (PMN) lineage [1]. G-CSF
also activates certain functions of mature PMN and sti-
mulates hematopoietic stem cell mobilization [2-6]. The
growth of neutrophilic granulocytes in vitro from pro-
genitor cells committed to neutrophils and monocytes
(CFU-GM) is absolutely dependent upon G-CSF and
sigmoidally increases with increasing G-CSF concentra-
tions [2,5,7,8]. A critical role for G-CSF in regulating
granulopoiesis in vivo has been demonstrated in G-CSF
null mice who have chronic neutropenia and severely
impaired granulopoietic responses to infection [6].
The biological activities of G-CSF are mediated by the
G-CSFR receptor (G-CSFR), a transmembrane protein
predominantly expressed on the surface of cells of the
neutrophil lineage [7]. Like other cytokine receptors, the
extracellular portion of the G-CSFR binds ligand and
the cytoplasmic tail transduces intracellular signals
[3,4,7]. Studies of mice with knock-out or knock-in
mutations in their G-CSFR gene have suggested the G-
CSFR generates unique signals required for PMN pro-
duction and marrow egress to maintain homeostatic
levels of circulating PMN during basal and stress granu-
lopoiesis [9-12].
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form decrease in myeloid cells in the bone marrow, and
defects in PMN activation [6,10]. Competitive repopula-
tion assays in these mice indicate G-CSF drives nearly
all of granulopoiesis under basal conditions and that G-
CSFR signals regulate the in vivo production and main-
tenance of both committed-myeloid progenitor cells and
primitive multipotential progenitors [12]. Additional
insights have come from mice expressing a chimeric G-
CSFR (GEpoR) comprised of the extracellular ligand-
binding domain of the G-CSFR fused to the cytoplasmic
domain of the erythropoietin receptor (EpoR) [13].
GEpoR mice retain the ability to produce PMN but
have chronic neutropenia, and despite near normal bone
marrow PMN levels, G-CSF treatment fails to mobilize
significant numbers of PMN into the peripheral blood.
The regulated manner in which PMN are produced
and released into the circulation suggests that positive
regulation of granulopoiesis via G-CSF/G-CSFR interac-
tions must be balanced by negative feedback loops
[14,15]. However, little is known about the mechanisms
downregulating G-CSFR surface expression to negatively
regulate granulopoiesis. An in vivo role for neutrophil
granule enzymes in both modulating PMN and stem
cell mobilization and in downregulating G-CSFR surface
expression on PMN was previously suggested by Jilma
[16]. Subsequent studies by Levesque et al identified
neutrophil elastase (NE) as a neutrophil granule enzyme
that promotes stem cell mobilization by cleaving chemo-
kines and chemokine receptors [17,18], such as stem cell
derived factor-1 (SDF-1) and its corresponding receptor,
CXCR4 [19].
Recent studies by our laboratory and others indicate
that NE also degrades G-CSF and inhibits G-CSF-stimu-
lated proliferative responses in vitro [20,21]. The para-
digm of both ligand and receptor cleavage provided by
SDF-1 and CXCR4 prompted us to investigate whether
NE also cleaves the G-CSFR to modulate its expression
and signaling and whether it might be the putative gran-
ule enzyme in PMN reported by Jilma that decreases G-
CSFR surface expression [16]. Here, we show that NE
proteolytically cleaves the G-CSFR to downregulate its
expression on PMN and that it also inhibits G-CSFR-
mediated granulopoiesis in vitro. These results suggest a
novel role for NE as a negative regulator of
granulopoiesis.
Materials and methods
Reagents and cell culture
Recombinant human G-CSF was generously provided by
Amgen (Thousand Oaks, CA). Other cytokines were
purchased from R&D Systems (Minneapolis, MN). Puri-
fied human NE was from Elastin Products Company,
Inc. (Owensville, MO). Cathepsin G (CG) and
azurocidin (AZ) were from Athens Research & Technol-
ogy (Athens, GA). Phenylmethylsulfonyl fluoride (PMSF)
and protease inhibitors were from Sigma-Aldrich Corp.
(St. Louis, MO). Anti-G-CSFR antibodies recognizing
the extracellular region of the human G-CSFR were
obtained from BD Biosciences (Palo Alto, CA). Strepta-
vidin-Cy5 was from Invitrogen (Carlsbad, CA) and bioti-
nylated anti-streptavidin antibody from Vector
Laboratories (Burlingame, CA). The polyclonal antibody
recognizing the distal tail of the murine and human G-
CSFR was obtained from Santa Cruz Inc (Santa Cruz,
CA). Fetal bovine serum (FBS), RPMI media, and
serum-free StemPro-34 media were from Invitrogen. Ba/
F3 and COS-7 cells transfected with the full-length
human G-CSFR cDNA, which have previously been
described, were grown in RPMI media containing 10%
FBS [22,23]. For culture of Ba/F3 cells, 10% WEHI con-
ditioned media was also added as a source of interleu-
kin-3 (IL-3).
Flow cytometric analyses
PMN (97% purity) were isolated from peripheral blood
of healthy human donors following appropriate
informed consent using Ficoll-Hypaque (d = 1.077) and
sedimentation in 3% dextran sulfate. Contaminating red
cells were removed by lysis in an ammonium chloride
solution (BD Biosciences). PMN (1 × 10
7 cells/ml) were
incubated at 37°C with or without 0-150 μg/ml NE, AZ,
or CG for varying times. Duplicate samples to which
10% serum or 1 mM PMSF was added during enzyme
incubations were also included. Reactions were stopped
by the addition of ice cold 10% FBS. G-CSFR expression
on PMN was analyzed following fixation in 1% parafor-
maldehyde using immunofluorescence staining and a
BD FACSCalibur Cytometer equipped with Cell Quest
software (BD Biosciences) as previously described [21].
Detection of proteolytic cleavage fragments of the G-
CSFR
PMN and stably transfected Ba/F3 cells expressing the
G-CSFR (1 × 10
7 cells/ml) were incubated with 150 μg/
ml NE in PBS at 37°C for 0-120 minutes. Reactions
were quenched by addition of 10% FBS and 1 mM
PMSF. Samples were centrifuged and the supernatants
containing the conditioned media collected. To detect
G-CSFR cleavage fragments, conditioned media and
whole cell lysates from the identical time points were
analyzed by immunoblot analysis. Cell pellets were lysed
as previously described [21], the samples (0.1 mg pro-
tein) loaded onto 10% polyacrylamide gels, transferred
to nitrocellulose membranes, and immunoblotted.
Colony assays
Bone marrow was aspirated from the posterior superior
iliac crest of healthy donors following appropriate
informed consent. The bone marrow mononuclear cell
fraction (BMMNC) was isolated using Ficoll-Hypaque.
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taining 2 mM glutamine and 20% FBS followed by
RPMI 1640 supplemented with 10% FBS and a final
wash in StemPro-34 media. BMMNC (1 × 10
4) were ali-
quoted into two fractions. One set was directly plated in
StemPro-34 containing 1% methylcellulose (Stem Cell
Technologies, Vancouver, BC, Canada), 1% BSA, 0.1
mM b-mercaptoethanol (2-ME), 2 mM L-glutamine, 10
μg/ml insulin, 200 μg/ml human iron-saturated transfer-
rin, recombinant human insulin (10 μg/ml), G-CSF (20
ng/ml), stem cell factor (50 ng/ml), GM-CSF (20 ng/
ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), and Epo (3 units/
ml). The second set of BMMNC was pre-incubated with
0-2 μg/ml NE at 37°C for 90 min and washed to remove
NE prior to plating in StemPro-34 media containing
growth factors. The plated cells were incubated at 37°C
for 14 days in a 5% CO2 humidified incubator and col-
ony forming units (CFU)-GM enumerated using an
Olympus CK2 inverted microscope equipped with a
MagnaFire Digital Camera (Olympus America, Melville,
NY).
Results
NE decreases G-CSFR surface expression on PMN
We initially investigated whether treatment of freshly
isolated PMN with NE altered surface expression of the
endogenous G-CSFR. G-CSFR surface expression on
PMN from healthy donors was analyzed before and
after treatment of the cells with NE using flow cytome-
try (n = 5). As shown in Figure 1A, a time-dependent
decrease in G-CSFR surface expression with near com-
plete loss at 2 h was observed following treatment of
PMN with NE.
To determine whether the decrease in G-CSFR surface
expression in response to NE was enzymatically-
mediated, 10% serum or 1 mM PMSF were included
during the incubations. These concentrations of serum
and PMSF have previously been shown to be sufficient
to inhibit the enzymatic activity of NE [17,18,21]. As
shown in Figure 1B, inclusion of 10% serum during
incubation of PMN with NE markedly diminished the
r e d u c t i o ni nG - C S F Rn u m b e r so b s e r v e di nr e s p o n s et o
NE. Serum inhibited by 50% the reduction in G-CSFR
surface expression observed after treatment of PMN
with NE (Figure 1B). Similar results were obtained when
PMN were treated with NE for shorter time periods and
when PMSF was substituted for serum (data not
shown). The diminished effect of NE on G-CSFR
expression when serum or PMSF was added suggested
the effect of NE was enzymatically mediated. We also
examined the effect of other azurophilic granule pro-
teases (CG and AZ) on G-CSFR expression over the
same concentration range as NE using PMN from the
same donors, and observed that only NE significantly
decreased G-CSFR surface expression (data not shown).
NE degrades the G-CSFR protein on PMN
To investigate whether the decrease in G-CSFR numbers
on PMN observed in response to NE was due to enzy-
matic degradation of the G-CSFR, we examined the G-
CSFR protein in whole cell lysates. As shown in Figure
2A, a single band of Mr~150 kDa corresponding to the
molecular weight of the fully-processed human G-CSFR
protein expressed at the cell surface was detected in
immunoblots of whole cell lysates from untreated PMN
using an antibody recognizing the FNIII domains in the
extracellular region of the G-CSFR. Notably, when PMN
were treated with NE, this band became undetectable by
30 min, and remained undetectable after 2 h. When
1 0 %s e r u ma n d1m MP M S Fw e r ei n c l u d e dd u r i n gt h e
incubations with NE, the ~150 kDa band did not disap-
pear and could still be detected at 2 h (Figure 2A, last
lane), similar to PMN that were not treated with NE.
In order to determine whether the inability to detect
the ~150 kDa receptor band on NE-treated PMN was
due to a loss of the antibody recognition site as a result
of enzymatic degradation, the blot in Figure 2A was
stripped and re-blotted with an antibody recognizing the
cytoplasmic tail of the G-CSFR. Immunoblot analysis of
whole cell lysates from untreated PMN using this anti-
body yielded multiple bands, including the 150 kDa
mature G-CSFR protein and a faint ~130 kDa band, two
prominent bands in the 80-110 kDa range, and two
faint lower molecular weight bands (Figure 2B). When
PMN were treated with NE, the 150 kDa band could no
longer be detected at 30 min and remained undetectable
throughout the duration of the 2 h incubation. The
intensity of the lower molecular weight bands increased
as the incubation time with NE increased and appeared
to correlate with the disappearance of the 150 kDa band
corresponding to the mature G-CSFR protein. In addi-
tion, this antibody detected a new ~50 kDa band in
PMN treated with NE which could not be detected at
any time point examined in untreated PMN. The new
band was detected within 30 min and the intensity of
this band increased with longer incubation periods over
the 2 h time period examined. The presence of 10% FBS
completely inhibited the appearance of the new band
and disappearance of the mature 150 kDa receptor spe-
cies (Figure 2B, last lane). These findings are consistent
with proteolytic degradation of the G-CSFR by NE.
Furthermore, the inability to detect the mature form of
the G-CSFR protein on NE-treated PMN with an anti-
body recognizing the extracellular region of the G-CSFR
and the ability to detect a new 50 kDa band in PMN
following treatment with NE solely with an antibody
recognizing the cytoplasmic tail of the G-CSFR support
a mechanism whereby the G-CSFR is degraded by NE
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portion of the G-CSFR.
Detection of G-CSFR cleavage fragments in conditioned
media
We next analyzed conditioned media from untreated
and NE-treated PMN for the presence of G-CSFR clea-
vage fragments to obtain confirmatory evidence that NE
proteolytically cleaves the G-CSFR. Proteolysis within
the membrane-exposed portion of the G-CSFR is pre-
dicted to result in the generation of cleaved fragments
of the extracellular portion of the G-CSFR that are
released into the conditioned media and detected as
lower molecular weight bands that should only be
apparent after NE treatment. As shown in Figure 3A,
immunoblot analysis of the conditioned media collected
from the same PMN from which whole cell lysates were
examined in Figure 2 using the antibody recognizing the
extracellular portion of the G-CSFR detected the pre-
sence of multiple lower molecular weight bands of Mr <
50 kDa following treatment of PMN with NE. Although
a prominent non-specific band of Mr ~50-55 kDa was
seen at all time points in the conditioned media both
Figure 1 Neutrophil elastase (NE) decreases G-CSFR expression on human PMN. Peripheral blood neutrophils (PMN) from healthy donors
(97% purity) were incubated (1 × 10
7 cells/ml) with 150 μg/ml NE at 37°C for the indicated times. G-CSFR surface expression was analyzed by
flow cytometry as described using a biotinylated anti-G-CSFR antibody recognizing FNIII domains in the extracellular region of the G-CSFR (BD
PharMingen) and a BD FACSCalibur Cytometer. A representative experiment from five independent experiments using neutrophils from five
different donors is shown. (A) Effect of NE treatment for the indicated times on G-CSFR expression on PMN. Cells incubated with an isotype-
matched control antibody (Iso) are shown as a negative control. (B) Effect of inclusion of 10% FBS (+) during incubation of PMN with NE. (C)
PMN were treated with 150 μg/ml of NE, azurocdin (AZ), or cathepsin G (CG) for 2 h, then the G-CSFR was analyzed by flow cytometry. Shown
is percent of fluorescence compared to maximum fluorescence at time 0.
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Mr < 50 kDa could only be detected in media harvested
from PMN that were treated with NE. Since the extra-
cellular domain of the G-CSFR is predicted to have a
Mr ~60 kDa, detection of bands smaller than this only
after treatment of PMN with NE supports a mechanism
involving cleavage of the G-CSFR in its extracellular
region. As expected, immunoblot analysis of whole cell
lysates from untreated COS-7 cells transfected with the
full-length G-CSFR cDNA (Figure 3A, last lane) and of
untreated PMN (Figure 2A) using the same antibody
yielded a 150 kDa band consistent with the mature
membrane-anchored G-CSFR protein [23,24]. The
appearance of the multiple lower molecular weight G-
CSFR species in conditioned media from NE-treated
PMN (Figure 3A) correlated with the time course
Figure 2 NE proteolytically cleaves the G-CSFR on PMN. PMN were treated with 150 μg/ml NE for the indicated times, the reactions
quenched by addition of 10% FBS and 1 mM PMSF, and the cells lysed. Samples were resolved on 10% polyacrylamide gels, transferred to
nitrocellulose, and the membranes immunoblotted with (A) the monoclonal antibody LMM741 recognizing FNIII domains in the extracellular
portion of the G-CSFR (BD PharMingen). The arrow indicates the full length G-CSFR. (B) The blot in (A) was stripped then reblotted with rabbit
polyclonal antibody recognizing the C-terminus of the G-CSFR (Santa Cruz). +FBS denotes lysates from PMN treated with NE for 120 min in the
presence of 10% FBS. The arrows indicate the full length G-CSFR and resultant C-terminus generated by NE cleavage. A representative blot from
three independent experiments (n = 3) is shown.
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Page 5 of 11Figure 3 Detection of G-CSFR cleavage fragments in conditioned media from NE-treated cells. (A) PMN and (B) Ba/F3 cells transfected
with the full-length G-CSFR cDNA were treated (1 × 10
7cells) with 150 μg/ml NE for the indicated times. Reactions were stopped by the
addition of 10% FBS and 1 mM PMSF, the samples centrifuged, and the supernatants containing the conditioned media collected and
immunoblotted with an antibody recognizing the FNIII domains in the extracellular region of the G-CSFR. Arrows indicate the extracellular G-
CSFR fragments generated by NE. A representative blot from three independent experiments (n = 3) is shown.
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CSFR by NE (Figure 2B). Proteolytic cleavage fragments
of the G-CSFR in the conditioned media of NE-treated
PMN were apparent within 60 min, at a time when
degraded forms of the G-CSFR protein could also be
detected in whole cell lysates from the same PMN sam-
ples treated with NE.
S i n c ew ep r e v i o u s l ys h o w e dt h a ti ns t a b l yt r a n s f e c t e d
Ba/F3 cells the ectopically expressed G-CSFR is cleaved
by NE [21], we also examined conditioned media from
these cells for the presence of cleavage fragments of the
G-CSFR. As shown in Figure 3B, treatment of Ba/F3
transfectants with NE resulted in the appearance of
multiple lower molecular weight G-CSFR cleavage frag-
ments in the conditioned media. Bands of Mr <5 0k D a
were detectable in the conditioned media by 30 min, a
time slightly earlier than their appearance in conditioned
media from NE-treated PMN.
NE inhibits G-CSFR-mediated CFU-GM growth
Since the growth of CFU-GM in vitro has been shown
to be absolutely dependent upon G-CSF, which trans-
duces signals through the G-CSFR [7,15], we investi-
gated the effects of treatment of myeloid progenitor
cells with NE on the signaling function of the G-CSFR.
For these studies, the effect of NE on the growth of
myeloid progenitor cells purified from the mononuclear
cell fraction of bone marrow (BMMNC) from healthy
human donors was examined (n = 4). Pre-treatment of
BMMNC with NE prior to their culture in methylcellu-
lose supplemented with G-CSF and other growth factors
reduced CFU-GM growth by as much as 75% (Figure 4).
The inhibitory effect of NE on CFU-GM growth was
also observed to be dose-dependent (data not shown).
Discussion
A remarkable feature of granulopoiesis is the regulated
production and release of PMN to maintain homeostatic
levels in the circulation during basal granulopoiesis and
to rapidly increase numbers during environmental stress
[15]. G-CSF is the major cytokine regulating granulopoi-
esis [3,6,7], and its regulatory capacity depends upon its
ability to bind to the G-CSFR. Thus, both G-CSF con-
centration and G-CSFR numbers modulate myeloid cell
responsiveness and, hence, PMN numbers. The physio-
logic processes that regulate G-CSF levels have been
well-characterized [7], but little is currently known
about the mechanisms modulating G-CSFR surface
expression.
Ligand-binding has been shown to trigger endocytosis
and internalization of most growth factor receptors,
which are then either recycled back to the cell surface
or degraded intracellularly [3,24]. Ligand-induced inter-
nalization decreases the number of surface receptors
and thereby serves to attenuate growth factor-induced
signals [25-27]. In the case of the G-CSFR, ligand bind-
ing has been shown to modulate G-CSFR surface
expression in vitro [23,28]. Following ligand binding, the
G-CSFR on immature myeloid cells, U937 cells, and
PMN is rapidly internalized and degraded [28]. More
than 70% of specifically bound G-CSF is internalized
after 5 min. Treatment of PMN with GM-CSF, TNF,
LPS, fMLP, TPA, or C5a also downregulates G-CSFR
numbers, while only TPA significantly reduces G-CSFR
numbers on immature cells. There is no evidence the
G-CSFR is recycled back to the cell surface.
Studies of naturally-occurring G-CSFR deletion
mutants isolated from patients with severe congenital
neutropenia (SCN) transforming to acute myelogenous
leukemia (AML) have provided evidence for the impor-
tance of downregulation of G-CSFR expression [29,30].
A critical cytoplasmic domain that mediates G-CSFR
internalization and degradation has been shown to be
deleted in cells from these patients, which exhibit
enhanced growth and survival signals to G-CSF
[21,23,31,32]. G-CSFR surface expression is prolonged
and G-CSF-mediated activation of Stat5 and Akt are
sustained in these cells, indicating that receptor downre-
gulation plays a critical role in extinction of G-CSFR
signals.
There is also evidence that the G-CSFR on PMN is
downregulated in vivo in response to G-CSF. Jilma et al
showed that a single injection of G-CSF decreased G-
CSFR numbers on PMN in humans by ~75% [16].
These effects were noted as early as 6 min, peaked at 90
min, and did not return to pre-treatment levels for 2
days. Notably, PMN numbers were transiently decreased
and plasma levels of the neutrophil granule enzyme
gelatinase b (also known as matrix metalloproteinase-9
or MMP-9) were increased 10-fold after G-CSF adminis-
tration, implying a role for gelatinase b in both decreas-
ing G-CSFR levels and PMN numbers. In related studies
of the in vivo effects of lipopolysaccharide (LPS) infusion
on G-CSFR expression, a significant negative correlation
between PMN activation and G-CSFR expression was
found [33]. The effects were reported to be independent
of LPS-induced increases in G-CSF levels in vivo,s u g -
gesting that PMN activation and G-CSFR expression are
tightly co-regulated.
In the current paper, we have identified an alternative
mechanism for modulating G-CSFR expression on PMN
involving the primary granule enzyme NE. Our data
provide the first evidence that NE cleaves the endogen-
ously expressed G-CSFR on PMN and inhibits G-CSFR-
mediated granulopoiesis in vitro. Treatment of PMN
with NE induced a time-dependent reduction in G-
CSFR surface expression and the appearance of G-CSFR
cleavage fragments in conditioned media from treated
PMN. Both serum and PMSF could prevent degradation
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Page 7 of 11Figure 4 Pretreatment of bone marrow-derived myeloid progenitors with NE inhibits granulocyte colony formation. Bone marrow
mononuclear cells (BMMNC) isolated from four healthy donors were left untreated or treated with 1 μg/ml NE for 90 min at 37°C. The cells
were then washed, resuspended in StemPro-34 serum-free media, and plated (1 × 10
4 cells) in serum-free Methocult containing 1%
methylcellulose, G-CSF (20 ng/ml), and a cocktail of recombinant growth factors as described in the Materials and Methods. CFU-GM were
enumerated after 14 days. Data are represented as the percent of CFU-GM colonies arising from NE-treated cells compared to untreated cells.
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enzymatic cleavage. The time-course for the appearance
of G-CSFR cleavage fragments in conditioned media
from NE-treated PMN correlated well with the decrease
observed in G-CSFR surface expression on treated PMN
as detected by flow cytometry. We also show that NE
abrogates proliferative signals generated by the G-CSFR
in myeloid progenitor cells, as indicated by the
decreased number of CFU-GM arising from NE-treated
marrow progenitor cells. Our data demonstrate that NE
cleaves the G-CSFR at a site within its extracellular por-
tion, within which lies the ligand-binding site for G-
CSF. Notably, proteolytic cleavage of the G-CSFR within
this region is predicted to modify the binding site for G-
CSF and thereby affect the sensitivity of cells to G-CSF,
consistent with our data.
We [21]and others [20] have previously reported that
NE also cleaves G-CSF and antagonizes its in vitro activ-
ity. However, unlike El-Ouriaghli et al who could not
demonstrate an effect of NE on the G-CSFR [20], we
reported that NE could also cleave the G-CSFR on
transfected Ba/F3 cells [21]. It is possible that El-Our-
iaghli’s group failed to observe an effect on the G-CSFR
due to the significantly longer period of culture (up to
seven days) in NE-containing media they used before
analyzing G-CSFR expression or because of the lower
pH (5.5 vs.7.2) of their reconstituted NE.
NE has been reported to cleave multiple substrates in
addition to G-CSF and the G-CSFR including SDF-1,
CXCR4, VCAM-1, CD14, CD23, and complement
receptor 1 (CR1) [17-19,34-37]. For many cytokine and
chemokine receptors that are cleaved by NE, the extra-
cellular ligand binding region is the site of cleavage
[17-19,36,38]. Our findings with NE and the G-CSFR
suggest a similar role for NE in regulating both cytokine
and its respective receptor levels as reported for SDF-1
and CXCR4 [19]. Inactivation of SDF-1/CXCR4 interac-
tions by NE was shown to induce hematopoietic stem
cell mobilization. In G-CSF-induced stem cell mobiliza-
tion, NE levels increase in vivo in the plasma and bone
marrow microenvironment where PMN accumulate
[17,36,39].
More recently, NE was reported to downregulate
expression of c-KIT (CD117), the receptor for SCF [18].
Decreased c-KIT expression and increased NE levels
were demonstrated in the marrows of mice receiving G-
CSF for stem cell mobilization. Similar to our findings
with the G-CSFR, a 2 h incubation with NE was
required to induce a 50% reduction in c-KIT surface
expression.
During G-CSF-induced stem cell mobilization, plasma
levels of NE dramatically increase reaching levels of
approximately 1 mg/ml. Within individual azurophilic
granules from activated PMN, concentrations of NE in
excess of 5 mM (150 mg/ml) have been measured.
Thus, the concentrations of NE (0-150 μg/ml) and
serum (a source of alpha-1 anti-trypsin) used in our
experiments are well within the ranges reported in vivo
[40-44].
The functional significance of our findings in vivo
remains speculative, as we did not directly examine this.
However, NE-induced downregulation of G-CSFR
expression in vivo could promote cellular egress or inhi-
bit further expansion of the myeloid compartment. A
possible scenario is that during stem cell mobilization,
release of NE from accumulating PMN in the bone mar-
row functions to inhibit granulopoiesis by degrading the
G-CSFR and thereby preventing progressive and uncon-
trolled neutrophilia.
Our findings may have particular relevance to under-
standing the pathogenesis of SCN. In the majority of
patients with this disease, mutations in the ELA2 gene
encoding NE have been identified, some of which result
in aberrant targeting of NE to the plasma membrane
[45]. It is possible that such NE mutants induce aberrant
and/or accelerated cleavage of the G-CSFR in some
cases of SCN.
Conclusions
Our findings add the G-CSFR to the growing list of
hematopoietic cytokine/chemokine receptors regulated
by NE, and suggest a novel pathway for regulating G-
CSFR levels at the cell surface in addition to transcrip-
tional controls and ligand-induced internalization. Clea-
vage of both G-CSF and the G-CSFR could provide an
additional mechanism for fine-tuning PMN numbers.
Future studies in humans to examine G-CSFR levels on
cells in the blood and marrow before, during, and after
stem cell mobilization, and during periods of environ-
mental stress such as infection, may help to clarify the
in vivo relevance of NE-induced cleavage of the G-
CSFR.
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